Joint analysis of multiple traits can result in the identification of associations not found through the analysis of each trait in isolation. In addition, approaches that consider multiple traits can aid in the characterization of shared genetic etiology among those traits. In recent years, parentoffspring trio studies have reported an enrichment of de novo mutations (DNMs) in neuropsychiatric disorders. The analysis of DNM data in the context of neuropsychiatric disorders has implicated multiple putatively causal genes, and a number of reported genes are shared across disorders. However, a joint analysis method designed to integrate de novo mutation data from multiple studies has yet to be implemented. We here introduce multiple-trait TADA (mTADA) which jointly analyzes two traits using DNMs from non-overlapping family samples. mTADA uses two single-trait analysis data sets to estimate the proportion of overlapping risk genes, and reports genes shared between and specific to the relevant disorders. We applied mTADA to >13,000 trios for six disorders: schizophrenia (SCZ), autism spectrum disorder (ASD), developmental disorders (DD), intellectual disability (ID), epilepsy (EPI), and congenital heart disease (CHD). We report the proportion of overlapping risk genes and the specific risk genes shared for each pair of disorders. A total of 153 genes were found to be shared in at least one pair of disorders. The largest percentages of shared risk genes were observed for pairs of DD, ID, ASD, and CHD (>20%) whereas SCZ, CHD, and EPI did not show strong overlaps in risk gene set between them. Furthermore, mTADA identified additional SCZ, EPI and CHD risk genes through integration with DD de novo mutation data. For CHD, using DD information, 31 risk genes with posterior probabilities > 0.8 were identified, and 20 of these 31 genes were not in the list of known CHD genes. We find evidence that most significant CHD risk genes are strongly expressed in prenatal stages of the human genes. Finally, we validated our findings for CHD and EPI in independent cohorts comprising 1241 CHD trios, 226 CHD singletons and 197 EPI trios. Multiple novel risk genes identified by mTADA also had de novo mutations in these independent data sets. The joint analysis method introduced here, mTADA, is able to identify risk genes shared by two traits as well as additional risk genes not found through single-trait analysis only. A number of risk genes reported by mTADA are identified only through joint analysis, specifically when ASD, DD, or ID are one of the two traits examined. This suggests that novel genes for the trait or a new trait might converge to a coregene list of the three traits.
Introduction
The analysis of multiple traits can help characterize the genetic architectures of complex disorders (Solovieff, et al., 2013) . One approach is to meta-analyze results derived from separate single-trait studies (Zhernakova, et al., 2011) . However, joint analysis with multiple traits can better accommodate heterogeneity of genetic effects of the same variants or genes across traits (Allison, et al., 1998; Galesloot, et al., 2014) . Numerous studies have jointly analyzed two or more traits and successfully identified shared common-variant associations (Giambartolomei, et al., 2014; Pickrell, et al., 2016; Lutz, et al., 2017; Turley, et al., 2018) ; however, none of these studies has examined rare variation from case-control (CC) data, or de novo variants for which mutations rates should be taken into account. For these rare variants, gene based tests have successfully identified genes associated with different disorders (He, et al., 2013; De Rubeis, et al., 2014; Iossifov, et al., 2014; Nguyen, et al., 2017) . Some recent studies have also shown that there are multiple risk genes that are shared between neurodevelopmental disorders (Hoischen, et al., 2014; Li, et al., 2016; Nguyen, et al., 2017) , and also with congenital heart disease (CHD) (Homsy, et al., 2015; Willsey, et al., 2018) . These results are based on the intersection among the top prioritized genes from each disorder; therefore, reported numbers of genes shared by multiple disorders remain low (Nguyen, et al., 2017; Willsey, et al., 2018) . Development of multi-trait rare-variant methods for neuropsychiatric disorders (NPDs) and related disorders will facilitate the understanding of this important aspect of genetic architecture for these phenotypes.
Currently, there is still a limitation in the risk gene identification for a single trait of NPDs and relevant disorders. One reason is that risk gene discovery is underpowered when sample sizes are limited, as well as when relative risks (RRs) are not large (He, et al., 2013; Nguyen, et al., 2017) . Multiple risk genes have been reported for developmental disorders (DD), intellectual disability (ID) and autism spectrum disorder (ASD) (De Rubeis, et al., 2014; Lelieveld, et al., 2016; Deciphering Developmental Disorders Study, 2017) thanks to large sample sizes and/or RRs (Nguyen, et al., 2017) . However, there are a few risk genes identified for schizophrenia (SCZ) and epilepsy (EPI) because of small RRs and small sample size respectively (Nguyen, et al., 2017) . Simply increasing sample size is an expensive solution and might not be feasible for some rare disorders. If the genetics overlap, methods that can leverage the information from one trait to increase power for risk-gene identification for another trait with smaller sample size or RRs could help in obtaining additional genes for these disorders.
Here, we have developed a new statistical model that combines de novo mutation information to identify shared and specific risk genes for two disorders. To illustrate the advantage of the new pipeline over its previous single-trait version, we have applied the pipeline to a large data set of different NPDs and CHD (~13,000 parent-offspring trios) and identified shared genes between each pair of these disorders. We have also used this pipeline to identify additional risk genes for each disorder by borrowing the information of other traits. The identification of shared genes is important for understanding the overlapping genetic information of these disorders.
Methods

2.1
The mTADA pipeline
Statistical models in mTADA
We developed the multi-trait Transmission And Denovo Association (mTADA) pipeline to analyze DNMs for any two given disorders using the computational framework of extTADA (Nguyen, et al., 2017) (Table 1) . The mTADA pipeline is gene-based and requires input data of the number of de novo mutations and mutation rate per gene. If the de novo mutations are stratified on the basis of predicted effect (e.g. 'missense', 'nonsense', etc.), then each geneannotation category should have its own mutation rate that reflects the predicted effects of the mutations within. In summary, for each gene, we consider four models " ( = 0. .3) reflecting four alternative hypotheses: the gene is associated with neither trait (H0), the first trait only (H1), the second trait only (H2), or both traits (H3). We assume prior probabilities " ( = 0. .3) for the four models. To build models for these hypotheses, we used single-trait models from TADA (He, et al., 2013) ; therefore, we first introduce TADA and then mTADA. Like TADA , mTADA divides mutations into different annotation categories (e.g., loss-of-function or missense variants), builds models for these categories, and then integrates information across models to infer results.
In TADA, for the single trait , for each variant/mutation category in each gene, all variants are collapsed and considered as one count ( . ) with .~( 2 . . ), in which . , and . are the sample size (family number), mutation rate and relative risk (RR) of the category. For a single trait, TADA compares two hypotheses for each gene: non-risk gene . = 1, and risk gene
. > 1 in which . follows a Gamma distribution: .~ ( ̅ . . , . ) with ̅ . being the mean relative risk (meanRR) across risk genes, and . being a dispersion parameter. Thus, TADA implies that a proportion of all genes ( . A ) are risk genes. In mTADA, with two traits and four models, we define . as the non-null RR for trait ( = 1,2), which we can describe in terms of .," for trait under the BC model as D = D,D = D,E > 1 for the first trait, and F = F,F = F,E > 1 for the second trait (Table 1) . Under the non-risk gene models for each trait,
The likelihood of the data across all genes can be computed as 
F : gene is associated with the second trait
E : gene is associated with both traits 
Therefore, we only estimated E inside mTADA. Bayesian models were built using the rstan package (Carpenter, et al., 2016) . We used Markov Chain Monte Carlo (MCMC) within rstan to estimate E . We also implemented another option for users to choose the automatic differentiation vibrational inference (ADVI) (Kucukelbir, et al., 2015) to estimate E . Convergence was diagnosed by the estimated potential scale reduction statistic ( Y ) and visualizing traces of results. The Locfit package (Loader, 2007) was used to obtain the mode, credible interval (CI) of E . We used the mode as the estimated value of E .
Inference of risk genes
For gene , the statistical support for the BC model is captured by its posterior probability
, abbreviated as PP0, PP1, PP2 or PP3 for a gene). Inference of risk genes shared by the two traits can be made based on PP3. To summarize the evidence for association with a given trait, we used the sum of posterior probabilities of models including the risk gene hypothesis for that trait (Barber, et al., 2010) , i.e. KD + KE for trait one and KF + KE for trait two. In this way, we can clearly see how trait two's data's support for risk genes may contribute to support for trait one.
Simulation analysis
Generation of simulated data
We simulated data under the mTADA model in Table 1 . A gene was assigned to one of the four groups (four models) by using the probability ( G , D , F , E ). We used D A = 0.05 and F A = 0.03 which are approximately equal to ASD, ID and DD results in our single-trait study (Nguyen, et al., 2017 We used simulated data to assess the correlation between true and observed E values and between PPs and observed false discovery rates (oFDRs). An oFDR at a PP threshold was defined as the number of false positive genes divided by the number of identified genes. To use mTADA for single traits, for the BC gene, we calculated KD + KE and KF + KE for the first and second trait respectively.
Comparison between single-trait and two-trait pipelines
We used AUCs (area under the Receiver Operating Characteristic (ROC) curve) to compare risk gene classification performance between mTADA and extTADA on single traits. To obtain AUCs, we calculated true and false positive rates for extTADA and mTADA across PP thresholds, and calculated the areas under these ROC curves. We set a threshold of PP=0.8 to compare gene counts between mTADA and extTADA.
2.3
Neuropsychiatric disease and congenital heart disease de novo mutation data
We used the DNM data collected by Nguyen, et al. (2017) and CHD data from Homsy, et al. (2015) . These data included 356 EPI trios, 5122 ASD trios, 4293 DD trios, 1012 ID trios, 1017 SCZ trios, and 1213 CHD trios. DNMs were annotated and classified into multiple categories as in our previous work (Nguyen, et al., 2017) . For NDDs (EPI, ASD, DD and ID) and CHD, we used two categories (Nguyen, et al., 2017) : loss-of-function (LoF) and missense damaging (MiD) DNMs. The LoF category included nonsense, essential splice site, and frameshift DNMs defined by Plink/Seq (Fromer, et al., 2014) while the MiD category included DNMs annotated as missense by Plink/Seq and predicted damaging by each of seven methods (Genovese, et al., 2016) : SIFT, Polyphen2_HDIV, Polyphen2_HVAR, LRT, PROVEAN, MutationTaster, and MutationAssessor. For SCZ, we used LoF, MiD and synonymous mutations within DNase I hypersensitive sites (DHSs) because this category showed significant DNM enrichment in SCZ probands (Takata, et al., 2016) and non-null meanRR in extTADA (Nguyen, et al., 2017) . Mutation rates were calculated as described by Fromer, et al. (2014) and Nguyen, et al. (2017) . extTADA was used to obtain the proportions of risk genes and the meanRR of each category for each disorder. These values were then used as input for mTADA to estimate π E and then calculate K" (i = 1. . N, j = 0. .3) for each pair of traits.
The MCMC algorithm, No-U-Turn Sampler (NUTS), in the package was used to estimate E . Two independent chains and 5000 steps for each chain were used in the sampling process. Only 1000 samples from each chain were chosen for further analyses.
We used results from new de novo studies to validate mTADA results. New CHD de novo data include 2,871 probands which consist of 2445 trios (1204 trios are inside the data set of extTADA and used in the primary analysis of this study) and 226 singletons (Jin, et al., 2017) . In addition, we used the whole-genome-sequencing (WGS) trio data for EPI (Hamdan, et al., 2017) to validate results of EPI, which include 197 trios not included in our mTADA analyses.
For further in silico validation and characterization genes identified by mTADA, GeNets (Li, et al., 2017) was used to test protein-protein interactions (PPIs). The STRING database (Szklarczyk, et al., 2017) was also used as an alternative source for PPIs. For GeNets, we used results from input genes and direct-connection candidate genes automatically inferred by GeNets. For STRING, we used input genes only to obtain final results. To examine expression information of identified genes, spatiotemporal transcriptomic data were obtained from BRAINSPAN (Miller, et al., 2014) , divided into eight developmental time points (four prenatal and four postnatal) (Lin, et al., 2015) , and analyzed by hierarchical clustering for developmental trajectories.
To test the significance of the overlap of two gene sets, a permutation approach was used. We chose two random gene sets whose lengths are the same as the two tested gene sets from the background genes (19358 genes from mTADA). This was carried out times ( = 10,000 in this study) and the numbers of overlapping genes were recorded in a vector . P value was calculated as ( ℎ( [ > G ]) + 1)/( ℎ( ) + 1)) in which G is the observed number of overlapping genes between the two tested gene sets.
Results
Because mTADA is a novel tool that analyzes multiple traits using de novo mutation and mutation rate data, we validated mTADA using data simulated under its model (Table 1) and compared gene-identification results with our a single-trait pipeline extTADA.
Results of mTADA on simulated data
We used D A = 0.05 and F A = 0.03 as described in the Method section and simulated different data sets from the combination of different values of E and MeanRRs.
Type I error of shared risk gene identification
We first estimated Type I error for identifying shared risk genes (i.e. associated with both traits). We simulated data with E = 0 and tested for shared risk genes using different thresholds of the posterior probability of Model III (PP3). Smaller PP3 thresholds correspond to increased Type I error levels. This error was smaller than 0.05 when PP3 > 0.8 ( Figure 1A) . Overall, the error decreased when meanRRs or sample sizes increased.
Correlations between posterior probabilities and observed false discovery rates.
We also calculated the correlation between PPs and observed FDRs (oFDRs) for all situations. Regarding PP3 and oFDRs, PP=0.8 and 0.5 were approximately with oFDR=0.1 and 0.25 respectively. Small meanRRs could create higher FDRs, but this affection was not very strong ( Figure 1B ). These results were also similar for other situations: genes were associated with only first trait, only second trait, single traits (e.g., only first trait and both traits) ( Figure S1 , S2).
Figure 1: Validation of shared risk gene identification using mTADA on simulated data. Left panels show the Type I error of the identification of risk genes for both traits: X-axes are posterior probabilities (PPs) of Model III while Y-axes are Type I errors. Right panels show the correlation between PPs (x axis) and observed false discovery rates (FDRs, y axis). These are for the combination of different sample sizes (ntrio) and mean relative risks (MeanGamma). ntrio and MeanGamma describe the information of two traits.
The correlation between simulated and estimated values of E was also assessed. For large meanRRs, high correlations were observed for all sample sizes. For smaller meanRRs (range here), E values were over-or underestimated ( Figure S3 ). However, these small differences were not much affected to main analyses (Figure 1 , S1, S2).
Power for single-trait risk gene discovery
We compared gene numbers identified by mTADA and extTADA using the same threshold PP > 0.8. For E = 0 (no overlapping information), mTADA and extTADA reported nearly the same positive gene numbers (Figure 2A ). However, mTADA identified more genes than extTADA 24, 87 when E increased. In addition, mTADA's gene counts were also higher than those of extTADA when higher meanRRs were used. 
Comparison of AUCs for single traits
We designed a simulation experiment to assess the performance in the classification of risk and non-risk genes. We applied extTADA to single-trait data from our simulated data. We then calculated AUCs for mTADA and extTADA using classification results from single-trait data. AUCs of both were equal when E = 0 ( Figure 2B ). However, AUCs of mTADA were higher than those of extTADA when E 's values were larger. In addition, mTADA also performed better extTADA with larger meanRRs.
3.2
Results of mTADA and extTADA on neuropsychiatric disease and CHD data mTADA was applied to family data of 15 pairs of six disorders (ASD, SCZ, DD, ID, EPI and CHD). A threshold PP > 0.8 was used to prioritize top genes. To compare between mTADA and extTADA, we also extracted top prioritized genes from extTADA using the same threshold PP > 0.8.
DD based results showed strong convergence with smaller credible intervals because of its large sample size as well as a high relative risks of DNMs (Figure 3 ). The highest E was observed for pairs of DD, ID, ASD and CHD ( E > 0.019). These disorders also had the highest percentage of genes that overlap if we only focused on gene risk-gene proportions (Figure 3 ). CHD and EPI had the lowest E (0.001) followed by SCZ-EPI (0.0023). Figure S4 shows sampling results of Gene count AUC A B the proportions of overlapping genes for each pair of these traits; and Table S1 describes results of D A , F A estimated by extTADA and E estimated by mTADA.
Regarding overlapping genes, the highest number was also observed for DD and ID (88 genes) followed by ASD-DD (67 genes) and ASD-ID (47 genes). Four pairs of traits (CHD-EPI, SCZ-EPI, CHD-SCZ, SCZ-ID) had no overlapping genes. In comparison with extTADA in the identification of overlapping genes, mTADA reported higher or equal gene numbers (Figure 3) . Table S2 shows full mTADA's results for these six disorders.
We also used mTADA to prioritize top genes for single traits and compared with extTADA. For DD and ID, mTADA always performed better extTADA (Figure 3) . Similar results were also observed for ASD; except for the pair ASD-SCZ in which mTADA was better than extTADA for SCZ but extTADA was better than mTADA for ASD. For CHD, EPI and SCZ, mTADA was better than extTADA when CHD was combined with DD. 
Figure 3: Results of real data. A) Estimated results of the overlapping proportion of risk genes ( E ) for 15 pairs of 6 disorders: schizophrenia (SCZ), congenital heart disease (CHD), intellectual disability (ID), developmental disorder (DD), autism spectrum disorder (ASD), epilepsy (EPI). The first, second and third panels shows the proportion of risk genes that overlap for two traits (=
Insights into top mTADA genes
Overlapping genes between two traits Using a threshold PP>0.8, 153 genes were supported by the two-trait model in at least one pair ( E > 0.8, Table S2 ). Seven genes (ARID1B, GABRB3, KCNQ2, STXBP1, SYNGAP1, TLK2, POGZ, SCN2A) were observed for at least six pairs of disorders (Table 2) . POGZ and SCN2A were present in eight pairs of disorders. POGZ was significant for pairs relating to ASD, DD, ID, CHD and SZ while SCN2A was significant for pairs relating to ASD, DD, EPI, ID and SCZ. We checked DNMs of these two genes. As expected, POGZ had no DNMs for CHD, and SCZN2A had no DNMs for EPI. Interestingly, in the latest CHD study (Jin, et al., 2017) , POGZ was one of the top CHD gene while no DNMs were observed for SCN2A. In addition, in the latest study of 6,753 parent-offspring trios with NDDs and EPI (Heyne, et al., 2018) , 16 DNMs were in POGZ, but only one DNM was from a patient who has both ID and EPI.
Significant genes of single traits
To better understand mTADA results, we focused on three disorders (EPI, CHD and SCZ) whose DN-based genes have not been reported as many as the three other disorders. We used the K. + KE ( = 1, 2) of mTADA to obtain a single-trait's PP for the BC gene in the analysis of each pair of two disorders. We used DD as the main trait to infer results of other trait.
CHD
There were 31 genes with PP>0.8 by combining CHD and DD. 20/31 was not in the list of known CHD genes and in the meta-analysis results of a recent CHD study of Jin, et al. (2017) (Figure 4) . We tested the PPIs of these 31 genes by using GeNets and STRING database. Based on GeNets, these genes were well connected to communities (Overall connectivity p < 2.2x10-e3, Figure 4) . Next, by using STRING database, the number of edges were also higher than expected between these 31 nodes (20 edges versus 9 expected edges, p = 0.00198). We used expression data to test these genes. The majority of these genes were strongly expressed in early to late-mid prenatal stages (Figure 4) .
Validation of CHD genes using an independent data set We used the data of Jin, et al. (2017) to validate these results (See Methods). First, we tested the top CHD genes from the independent data set which include 1241 trios and 226 cases from Jin, et al. (2017) . From the 1241 trios, three genes (CTNNB1, CUL3, LZTR1) of the 20 novel genes had LoF or MiD DNMs (p<2.00e-4, Figure 4 ). In addition, CUL3 had one LoF variant from case data. These three genes had only one DNMs in the primary analysis, and were not called as significant genes by extTADA. We also ran extTADA on the 1241 trios, and saw that 4 of the 31 genes had PP>0.8 ( Figure 4 ). As expected, extTADA results of the majority of these 31 genes had low PPs because these genes had only 0 or 1 DNMs. Next, we compared our 31 genes with the top 25 genes meta-analyzed by Jin, et al. (2017) . 8/31 were in the 25-gene list (p < 9.99e-05).
To better understand the performance of mTADA on the combination of CHD and other disorders, we applied mTADA to the independent data set only and the combined data set. First, we ran mTADA on the independent 1241-trio data. Similar to the primary analysis, we also saw high overlaps between CHD, ASD, DD and ID (Figure 4) . By combining CHD and DD, 24 genes had PP>0.8. There were 6 overlapping genes between the 31 genes and the 24 genes (p < 9.99e-05). In these six genes, two genes NSD1 and CTNNB1 showed the benefit of using mTADA. Both genes had only one LoF DNM and did not show significant results in the original study of 1204 trios (Homsy, et al., 2015) as well as extTADA, but had highly significant PPs from mTADA (PP>0.97). Next, mTADA was applied to full 2451 trios. Estimated E values were similar to those of 1204 trios (Figure 4 ). There were 57 genes with PP>0.8.19/57 genes were in the 31 genes (p < 9.99e-05). (posterior probabilities, PPs, > 0.8) identified by mTADA using the data set of Homsy, et al. (2015) Homsy, et al. (2015) , Jin, et al. (2017) Jin, et al. (2017) for their top 25 genes. The last column describes PPs of extTADA for an independent trio data of Jin, et al. (2017) Jin, et al. (2017) : top panels are for an independent data set while bottom panels are for full data sets.
Figure 4: Congenital heart disease (CHD) results by using developmental disorder (DD) information. This is the top 31 genes
EPI
There were 15 genes with PP>0.8 by combining EPI and DD. Similar to top CHD genes, these genes were connected to communities (Overall connectivity p<2.2x10-e3, Figure S5 ) by using GetNets. They also had more interactions than expected by using the STRING database (22 edges versus 2 expected edges, p = 1.11e-05). Four genes GABBR2, HECW2, MLL, WDR19 were not in the list of known EPI genes. GABBR2 was reported as a top gene by extTADA (PP=0.97), but HECW2, MLL, WDR19 had only PP<0.3 in extTADA. Interestingly, both GABBR2, HECW2 had DNMs in a WGS study recently (Hamdan, et al., 2017) . We also used expression data to test these EPI genes. Differently from CHD, these genes were expressed in different stages of the human brain ( Figure S5 ).
SCZ
There were 10 genes with PP>0.8 including AUTS2, BRPF1, HIST1H1E, MAP4K4, MKI67, POGZ, SCN2A, SETD1A, SYNGAP1, TAF13. These were significantly connected to 
